# US 2025/0144056 A1 · Antimicrobial host defense peptide-inducing compositions and methods of production and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144056 A1
- Document ID: US20250144056A1
- Status: Published application
- Kind: A1
- Application number: 18/834,102
- Filed: 2023-01-31
- Published: 2025-05-08
- Earliest claimed: 2022-01-31
- Assignees: The Board of Regents for the Oklahoma Agricultural and Mechanical Colleges
- Applicants: Board of Regents for the Oklahoma Agricultural and Mechanical Colleges
- Inventors: Guolong ZHANG; Melanie Anne WHITMORE
- Web page: https://patentgrep.com/patent/US20250144056A1

## CPC

- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 35/00: Antineoplastic agents
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/04: Immunostimulants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions are disclosed that include a combination of at least one histone deacetylase inhibitor with at least one DNA or histone methyltransferase inhibitor. The combination of the histone deacetylase inhibitor with the methyltransferase inhibitor synergistically induces antimicrobial host defense peptide gene expression.

## Claims

### Claim 1

A composition, comprising:
(a) at least one histone deacetylase inhibitor; and
(b) at least one methyltransferase inhibitor selected from a DNA methyltransferase inhibitor and/or a histone methyltransferase inhibitor.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the at least one histone deacetylase inhibitor of (a) is selected from the group consisting of butyrate, phenylbutyrate, 4-phenylbutyric acid, β-hydroxybutyrate, vorinostat (suberoylanilide hydroxamic acid, SAHA), entinostat (MS-275), panobinostat (LBH589), mocetinostat (MGCD0103), belinostat (PXD101), romidepsin (FK228, depsipeptide), MC1568, tubastatin A, givinostat (ITF2357), dacinostat (LAQ824), CUDC-101, quisinostat (JNJ-26481585), pracinostat (SB939), PCI-34051, diallyl disulfide, depudecin, droxinostat, abexinostat (PCI-24781), RGFP966, AR-42, ricolinostat (ACY-1215), psammaplin A, tacedinaline (CI994), fimepinostat (CUDC-907), M344, tubacin, RG2833 (RGFP109), resminostat, BRD3308, SIS17, SR-4370, pimelic diphenylamide 106, NKL 22, azumamide E, tinostamustine (EDO-S101), SKLB-23bb, TH34, suberohydroxamic acid, UF010, WT161, valproic acid, 2-hexyl-4-pentynoic acid, tucidinostat (Chidamide), TMP195, TMP269, BRD73954, BG45, domatinostat (4SC-202), CAY10603, CAY10398, LMK-235, splitomicin, santacruzamate A (CAY10683), nexturastat A, HPOB, curcumin, divalproex sodium, scriptaid, GSK3117391, BML-210 (CAY10433), sulforaphane, raddeanin A, isoguanosine, sinapinic acid, tasquinimod, parthenolide, m-carboxycinnamic acid bis-hydroxamide, MC1742, JNJ-26481585, apicidin, HC toxin, oxamfaltin, bufexamac, KD5170, dihydrochlamydocin, 1-alaninechlamydocin, trapoxin A, microsporin A, largazole, sirtinol, inauhzin, SRT1720, SRT2104, SRT3025, CAY10591, CAY10602, thiomyristoyl, AGK2, JGB1741, salermide, AK-7, JFD00244, BML-278, pinosylvin, theobromine, EX-527, piceatannol, fisetin, vitexin, orientin, hyperforin, butein, ursolic acid, epicocconigrone, kaempferol, marein, zerumbone, lycorine, (S)-allylmercaptocysteine, and combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein (b) comprises at least one DNA methyltransferase inhibitor selected from the group consisting of decitabine, azacitidine, 2′-deoxy-5-fluorocytidine, thioguanine, zebularine, gamma-oryzanol, β-thujaplicin, procainamide, bobcat339, SGI-1027, RG108, RSC-133, SW155246, genistein, ellagic acid, rosmarinic acid, and combinations thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein (b) comprises at least one histone methyltransferase inhibitor selected from the group consisting of BIX01294, UNC0224, UNC0321, UNC0631, UNC0638, UNC0642, UNC0646, UNC1999, UNC6852, BRD9539, BRD4770, sinefungin, tazemetostat, nanaomycin A, lirametostat, 3-deazaneplanocin A, chaetocin, A-366, EPZ005687, EPZ011989, EPZ6438, GSK126, GSK343, GSK503, CM-272, CPI-169, CPI-360, EBI-2511, MS1943, JQEZ05, El1, (R)-PFI-2, PF-06726304, ZLD1039, and combinations thereof.

### Claim 5 (depends on 1)

The composition of claim 1, further comprising a pharmaceutically acceptable carrier or excipient.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the pharmaceutically acceptable carrier or excipient is aqueous.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the pharmaceutically acceptable carrier or excipient is oil-based.

### Claim 8 (depends on 1)

The composition of claim 1, further defined as a nutritional composition.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the nutritional composition is an animal feed.

### Claim 10 (depends on 8)

The composition of claim 8, wherein the nutritional composition is a nutritional supplement.

### Claim 11 (depends on 8)

The composition of claim 8, further comprising at least one additional ingredient selected from the group consisting of a thickener, a flavoring, a diluent, an emulsifier, a dispersing aid, a bulking agent, a binder, and combinations thereof.

### Claim 12 (depends on 1)

The composition of claim 1, wherein (a) is butyrate, and (b) is selected from the group consisting of BIX01294, A-366, and UNC1999.

### Claim 13 (depends on 1)

The composition of claim 1, wherein (a) is butyrate, and (b) is selected from the group consisting of SGI-1027 and azacytidine.

### Claim 14 (depends on 1)

The composition of claim 1, wherein (a) is vorinostat, and (b) is BIX01294.

### Claim 15 (depends on 1)

The composition of claim 1, wherein (a) is mocetinostat, and (b) is of BIX01294, A-366, and UNC1999.

### Claim 16 (depends on 1)

The composition of claim 1, wherein (a) is mocetinostat, and (b) is selected from the group consisting of SGI-1027 and azacytidine.

### Claim 17 (depends on 1)

A method of inducing expression of at least one antimicrobial host defense peptide, the method comprising the step of:
contacting at least one cell with the composition of claim 1 under conditions that allow for expression of the at least one antimicrobial host defense peptide.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one antimicrobial host defense peptide is selected from the group consisting of AvBD1, AvBD2, AvBD3, AvBD4, AvBD5, AvBD6, AvBD7, AvBD8, AvBD9, AvBD10, AvBD14, CATH2, CATHB1, and combinations thereof.

### Claim 19 (depends on 1)

A method, comprising the step of:
administering to an animal the composition of claim 1.

### Claim 20

A method, comprising the step of:
administering to an animal, either simultaneously or wholly or partially sequentially:
(a) at least one histone deacetylase inhibitor; and
(b) at least one methyltransferase inhibitor selected from a DNA methyltransferase inhibitor and/or a histone methyltransferase inhibitor.
